DelMar Pharmaceuticals, Inc. (DMPI) Trading Up 5.2%
DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) shares were up 5.2% on Monday . The company traded as high as $0.94 and last traded at $0.93. Approximately 675,578 shares traded hands during trading, a decline of 19% from the average daily volume of 838,291 shares. The stock had previously closed at $0.88.
A number of research analysts recently weighed in on DMPI shares. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price objective on shares of DelMar Pharmaceuticals in a report on Thursday. Maxim Group reaffirmed a “hold” rating on shares of DelMar Pharmaceuticals in a report on Monday, September 11th. Finally, Dawson James reaffirmed a “buy” rating on shares of DelMar Pharmaceuticals in a report on Tuesday, August 8th.
The firm has a 50-day moving average price of $1.11 and a 200 day moving average price of $2.10. The firm’s market cap is $20.04 million.
A hedge fund recently bought a new stake in DelMar Pharmaceuticals stock. Franklin Resources Inc. bought a new stake in DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 1,076,923 shares of the company’s stock, valued at approximately $2,477,000. 13.74% of the stock is owned by institutional investors.
About DelMar Pharmaceuticals
DelMar Pharmaceuticals, Inc is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer.
Receive News & Stock Ratings for DelMar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.